Skip to content
TheChatArchiveThe Chat Archive
Claudeclaude-3-5-sonnet-20241022· AnthropicHugging Face LMArena Human Preference 140K

Dr. Apple wants to study a drug to manage diabetes in adolescents. The researcher plans…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Qwenqwen-max-2025-01-25’s answer.
  1. User

    Dr. Apple wants to study a drug to manage diabetes in adolescents. The researcher plans to use an electronic informed consent (eIC) form presented on a tablet device. Per FDA guidance on the “Use of Electronic Consent in Clinical Investigations” (2016), can adolescent subjects assent using an electronic device? No, the eIC cannot be used for assent from pediatric subjects No, the eIC cannot be used because this is a FDA-regulated clinical investigation Yes, the eIC process can be used for assent Yes, the eIC process can be used but only if the subject can sign their own name electronically

  2. Claude Assistant

    The correct answer is:

    Yes, the eIC process can be used for assent

    Here's the analysis:

    1. According to the FDA's 2016 guidance on "Use of Electronic Informed Consent in Clinical Investigations":
    • Electronic informed consent (eIC) can be used for both consent and assent processes
    • The guidance explicitly addresses pediatric subjects and allows for electronic assent
    • There are no restrictions preventing the use of eIC specifically for pediatric populations
    1. Key points supporting this:
    • The FDA guidance encourages the use of interactive and engaging electronic elements that may actually be particularly beneficial for adolescent subjects
    • eIC can incorporate age-appropriate explanations and multimedia elements that help younger subjects better understand the study
    • The electronic format can make the assent process more accessible and comprehensible for adolescents
    1. Important considerations when using eIC for assent:
    • The eIC system must still meet all regulatory requirements for documentation
    • The process should include methods to verify the identity of the person providing assent
    • Parents/guardians must still provide documented permission
    • The system should be age-appropriate and understandable for the adolescent population

    Why the other options are incorrect:

    • "No, the eIC cannot be used for assent from pediatric subjects" - This directly contradicts the FDA guidance
    • "No, the eIC cannot be used because this is a FDA-regulated clinical investigation" - The FDA explicitly allows eIC in regulated clinical investigations
    • "Yes, the eIC process can be used but only if the subject can sign their own name electronically" - The guidance does not require electronic signature capability as a prerequisite for using eIC

    The FDA guidance supports using modern technology to facilitate the informed consent/assent process while maintaining appropriate protections for research subjects, including adolescents.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.